728 related articles for article (PubMed ID: 23457035)
1. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapy in hepatocellular carcinoma.
Huynh H
Biochem Pharmacol; 2010 Sep; 80(5):550-60. PubMed ID: 20371362
[TBL] [Abstract][Full Text] [Related]
3. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Zhu AX
Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
6. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Zhu AX
Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
Kudo M
Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
[TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Kim HY; Park JW
Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy and synergies by combination.
Wörns MA
Dig Dis; 2013; 31(1):104-11. PubMed ID: 23797131
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
11. Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Dekervel J; van Pelt J; Verslype C
Curr Opin Oncol; 2013 Jul; 25(4):409-16. PubMed ID: 23680714
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors in development for hepatocellular carcinoma.
Wörns MA; Galle PR
Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
[TBL] [Abstract][Full Text] [Related]
13. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary management of hepatocellular carcinoma: where are we today?
Marrero JA
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S3-10. PubMed ID: 23457037
[TBL] [Abstract][Full Text] [Related]
15. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors to treat liver cancer.
Huynh H
Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
[TBL] [Abstract][Full Text] [Related]
17. Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Kudo M
Dig Dis; 2011; 29(3):316-20. PubMed ID: 21829023
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
Zhu AX
Semin Oncol; 2012 Aug; 39(4):493-502. PubMed ID: 22846866
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Weintraub JL; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1123-34. PubMed ID: 23562168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
